(NASDAQ)
81.89
-1.41   (-1.69%)
After Hours: 82.19 +0.30 (+0.37%)
Volume (24h) Market Cap. Day Range 52w Range
2.64M 5.29B 81.59 - 92.00 9.18 - 92.00
Jan-14-21 03:11AM With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting EdgeBarrons.com
Jan-11-21 08:02AM The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex PharmaceuticalsZacks
Jan-08-21 09:01AM CRISPR Gene Editing Stocks Up After Intellia's Pipeline UpdateZacks
Jan-07-21 04:24AM Genetics Stocks Pop After Intellia Offers Update For Gene-Editing DrugsInvestor's Business Daily
02:33AM Genetics Stocks Pop After Intellia Offers Update For Gene-Editing DrugsInvestor's Business Daily
Jan-07-21 01:05AM Why Intellia Therapeutics Stock Is Soaring TodayMotley Fool
08:42AM 3 Biotech Technological Developments to Watch Out For in 2021Zacks
Jan-07-21 07:30AM Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021GlobeNewswire
Jan-06-21 11:00AM A New Gene-Editing Technique May Be Able to Help Children Who Prematurely AgeBarrons.com
Jan-04-21 09:27AM 5 Disruptive Biotech Stocks With Solid Long-Term PotentialZacks
Jan-01-21 01:22AM Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Could Be 41% Below Their Intrinsic Value EstimateSimply Wall St.
Dec-30-20 10:42AM The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana TherapeuticsZacks
Dec-29-20 12:27PM Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking TodayMotley Fool
09:37AM 5 Biotech Stocks That Have Gained More Than 200% in 2020Zacks
Dec-21-20 04:24AM Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestor's Business Daily
12:43PM Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestor's Business Daily
Dec-16-20 09:33AM Is NTLA A Good Stock To Buy Now?Insider Monkey
Dec-12-20 09:00AM Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT DeficiencyGlobeNewswire
Dec-10-20 02:03AM CRISPR Gene Editing: Owning the Future of MedicineZacks
Dec-09-20 11:06AM Gene-Editing Stocks Skyrocket in $1.6 Billion Boom After DataBloomberg
Dec-07-20 04:20AM Here Are The Winners Of This Year's Biggest Blood Cancer MeetingInvestor's Business Daily
11:58AM Here Are The Winners Of This Year's Biggest Blood Cancer MeetingInvestor's Business Daily
Dec-07-20 10:06AM Here Are The Winners Of This Year's Biggest Blood Cancer MeetingInvestor's Business Daily
Dec-05-20 10:00AM Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual MeetingGlobeNewswire
Dec-04-20 04:01AM Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
08:00AM New Results on Blood Disorder Treatments Are Coming. Watch These Stocks.Barrons.com
Dec-03-20 08:41AM Intellia (NTLA) Catches Eye: Stock Jumps 7.8%Zacks
Dec-01-20 09:30AM Intellia Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire
Nov-30-20 04:01AM Intellia Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire
Nov-11-20 07:30AM Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease TreatmentsGlobeNewswire
Nov-09-20 07:30AM Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin AmyloidosisGlobeNewswire
05:57AM Analysts Have Lowered Expectations For Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest ResultsSimply Wall St.
Nov-06-20 05:30AM Intellia Therapeutics, Inc. (NTLA) Q3 2020 Earnings Call TranscriptMotley Fool
Nov-05-20 07:30AM Intellia Therapeutics Announces Third Quarter 2020 Financial ResultsGlobeNewswire
06:15AM Intellia Therapeutics, Inc. to Host Earnings CallACCESSWIRE
Oct-29-20 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company UpdatesGlobeNewswire
Oct-27-20 10:35AM Benzinga's Top Upgrades, Downgrades For October 27, 2020Benzinga
Oct-19-20 07:30AM Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)GlobeNewswire
Oct-07-20 04:20AM Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing TechnologyGlobeNewswire
10:04AM Nobel Prize for Gene-Editing Innovators Boosts Crispr Therapeutics and Other StocksBarrons.com
Oct-05-20 07:30AM Intellia Therapeutics Names John F. Crowley to Board of DirectorsGlobeNewswire
Sep-29-20 08:20AM Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based TreatmentGlobeNewswire
Sep-28-20 08:00AM Intellia Therapeutics to Present at Chardan’s Virtual 4th Annual Genetic Medicines ConferenceGlobeNewswire
Sep-22-20 09:43AM Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 50%TipRanks
Sep-18-20 09:31AM Benzinga's Top Upgrades, Downgrades For September 18, 2020Benzinga
Sep-02-20 08:00AM Intellia Therapeutics to Present at Baird’s 2020 Virtual Global Healthcare ConferenceGlobeNewswire
Aug-11-20 11:10AM We're Not Worried About Intellia Therapeutics' (NASDAQ:NTLA) Cash BurnSimply Wall St.
11:06AM How Much Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Do Institutions Own?Simply Wall St.
Aug-06-20 09:15AM Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue EstimatesZacks
07:30AM Intellia Therapeutics Announces Second Quarter 2020 Financial ResultsGlobeNewswire
Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Cap:    |  Volume (24h):